{"product_id":"bd-bcg-matrix","title":"Becton Dickinson Boston Consulting Group Matrix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBecton Dickinson: BCG Matrix Snapshot\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eBecton Dickinson's BCG Matrix snapshot indicates where its core medical‑device franchises likely sit amid evolving healthcare demand-spotting potential Stars in high‑growth areas, Cash Cows in established product lines, and offerings that may need reinvestment or divestment. This preview outlines quadrant‑level positioning and strategic implications; the full BCG Matrix provides complete placements, data‑driven recommendations, and actionable capital‑allocation guidance. Purchase the full report to receive an editable Word analysis and an Excel summary for immediate use and confident decision‑making.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConnected Medication Management Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBDs Alaris infusion pumps and Pyxis automated dispensing cabinets lead hospital medication-safety automation, holding an estimated combined market share ~28% in acute-care infusion and ADCs in 2024, driven by digital workflow adoption and a 7-9% CAGR in connected medication management software through 2023-25.\u003c\/p\u003e\n\u003cp\u003eHospitals prioritizing error reduction and pharmacy labor optimization drive SaaS growth for BD, with subscription revenue rising ~15% YoY in 2024 and capex and service contracts funding continuous cybersecurity and EHR interoperability upgrades.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMolecular Diagnostics and BD COR System\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBD has moved diagnostic leadership into high-growth molecular testing with BD COR and BD MAX; BD reported molecular diagnostics revenue of about $1.6 billion in FY2024, up ~12% year-over-year, driven by high-throughput infectious disease and women's health panels.\u003c\/p\u003e\n\u003cp\u003eThese systems meet growing post-pandemic demand-global molecular diagnostics market grew ~9% in 2024 to $12.5 billion-and BD captures a top-three share in clinical labs, though expanding test menus needs continued R\u0026amp;D investment (~10% of diagnostics revenue).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSingle-Cell Multiomics and Flow Cytometry\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eThe BD Biosciences segment leads high-end research tools-BD Horizon RealBlue and RealYellow reagents plus advanced cell sorters-driving roughly 12-15% annual growth in single-cell multiomics and flow cytometry sales (2024 est.), with consumables recurring revenue ~55% of segment revenue.\u003c\/p\u003e\n\u003cp\u003ePersonalized medicine and immunology research fuel demand; market for single-cell tools hit ~$4.2B in 2024 and BD holds an estimated 25-30% share, keeping a dominant position but requiring ~USD 400-500M annual R\u0026amp;D and capex to stay ahead of genomic-tech shifts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGLP-1 Drug Delivery Solutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eBDs pre-fillable syringe unit sits in Stars: rapid GLP-1 demand (obesity\/diabetes) has driven \u0026gt;40% CAGR in device volumes since 2022, making BD a primary supplier to top pharma partners and capturing an estimated 50%+ share of injector supply by 2025.\u003c\/p\u003e\n\u003cp\u003eKeeping supply parity needs heavy capex: BD announced a $1.2B capacity expansion plan in 2024 to meet projected demand of ~1.5 billion GLP-1 doses\/year by 2030, or risk supply bottlenecks and lost revenue.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eHigh growth: device volumes +40% CAGR since 2022\u003c\/li\u003e\n\u003cli\u003eMarket share: ~50%+ injector supply by 2025\u003c\/li\u003e\n\u003cli\u003eCapex: $1.2B expansion announced 2024\u003c\/li\u003e\n\u003cli\u003eDemand: ~1.5B GLP-1 doses\/year projected by 2030\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Peripheral Intervention Devices\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAdvanced Peripheral Intervention Devices: BD's interventional unit grew revenue ~6% in 2024, driven by Venovo venous stent and PowerPICC sales, targeting venous disease and oncology in an aging population needing minimally invasive care.\u003c\/p\u003e\n\u003cp\u003eBD keeps leadership via ongoing clinical trials (50+ studies globally by 2025) and iterative product updates to defend a high share vs. smaller challengers.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 revenue growth ~6%\u003c\/li\u003e\n\u003cli\u003e50+ clinical studies by 2025\u003c\/li\u003e\n\u003cli\u003eKey products: Venovo stent, PowerPICC\u003c\/li\u003e\n\u003cli\u003eMarket: aging population, minimally invasive vascular procedures\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBD growth surge: dominant pre-fill syringes \u0026amp; Alaris\/Pyxis SaaS fueling rapid expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBD Stars: pre-fillable syringes (50%+ injector share by 2025; \u0026gt;40% device CAGR since 2022; $1.2B capex 2024) and Alaris\/Pyxis infusion\/ADC (~28% acute-care market share 2024; 7-9% connected SaaS CAGR 2023-25; subscription rev +15% YoY 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eBusiness\u003c\/th\u003e\n\u003cth\u003e2024 metric\u003c\/th\u003e\n\u003cth\u003e2025 outlook\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePre-fillable syringes\u003c\/td\u003e\n\u003ctd\u003e50%+ share; $1.2B capex\u003c\/td\u003e\n\u003ctd\u003emeet ~1.5B doses\/yr by 2030\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAlaris\/Pyxis\u003c\/td\u003e\n\u003ctd\u003e~28% share; SaaS +15% YoY\u003c\/td\u003e\n\u003ctd\u003e7-9% SaaS CAGR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eComprehensive BCG Matrix review of Becton Dickinson's units with strategic guidance on Stars, Cash Cows, Question Marks, and Dogs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eOne-page BCG Matrix placing Becton Dickinson units in quadrants for quick strategic decisions and investor briefings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBD Vacutainer Blood Collection Systems\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBD Vacutainer blood collection systems are the global gold standard, with BD (Becton Dickinson and Company, NYSE: BDX) holding an estimated \u0026gt;50% global market share in tube-based phlebotomy as of 2025 and serving hospitals and labs in 190+ countries.\u003c\/p\u003e\n\u003cp\u003eThe market is mature, growing ~2-3% annually; Vacutainer products generate high free cash flow-BD reported medical segment operating margin ~18% in FY2024-while requiring low promotional spend.\u003c\/p\u003e\n\u003cp\u003eThose stable profits fund BD's higher-growth bets in molecular diagnostics and digital health, where BD targets double-digit CAGR investments and M\u0026amp;A to boost recurring revenue and innovation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStandard Hypodermic Needles and Syringes\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAs one of the world's largest makers of standard hypodermic needles and syringes, Becton Dickinson (BD) captures unmatched economies of scale in a low-growth, high-volume market; global disposable syringe demand was ~20 billion units in 2024. \u003c\/p\u003e\n\u003cp\u003eUnit margins are lower than for specialty devices, but volume yields stable revenue-BD reported $2.8 billion in syringe\/needle segment sales in FY2024-providing predictable cash flow. \u003c\/p\u003e\n\u003cp\u003eR\u0026amp;D needs are minimal, so BD can allocate free cash to service ~ $4.5 billion net debt (2024) and sustain a dividend (2024 payout ratio ~25%), making this a classic cash cow. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePeripheral IV Catheters\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBD's Medication Delivery Solutions unit holds roughly 30-35% share of the global peripheral IV catheter market (2024 estimate), making these staples in nearly all acute-care settings; annual catheter revenues are estimated at ~$900M within BD Medical (FY2024 pro forma).\u003c\/p\u003e\n\u003cp\u003eThe product is mature with low obsolescence, high gross margins (~45%-55%) from long-term hospital contracts and brand trust, so it acts as a reliable cash cow.\u003c\/p\u003e\n\u003cp\u003eCash flow from peripheral IVs finances BD Medical's push into complex, digitally enabled infusion systems and sensors, supporting R\u0026amp;D and M\u0026amp;A-BD reported $1.8B in Medical segment operating cash flow in FY2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInfection Prevention and ChloraPrep\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eChloraPrep holds a leading share (\u0026gt;40% in US perioperative skin antiseptics as of 2024) in a low-growth surgical site infection (SSI) prevention market, driven by regulation like CMS and Joint Commission standards that keep demand stable.\u003c\/p\u003e\n\u003cp\u003eThe line generates steady cash for Becton Dickinson (BD), with disposable margins supported by scale; 2024 BD Surgical Solutions revenue ~USD 3.2bn implies predictable contribution without need for heavy marketing spend.\u003c\/p\u003e\n\u003cp\u003eFocus on incremental packaging and applicator improvements-easier single-dose delivery, reduced waste-maintains margins and extends lifecycle in a mature category.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket share \u0026gt;40% (US, 2024)\u003c\/li\u003e\n\u003cli\u003eSSI market growth \u0026lt;3% CAGR\u003c\/li\u003e\n\u003cli\u003eBD Surgical Solutions rev ~USD 3.2bn (2024)\u003c\/li\u003e\n\u003cli\u003eStrategy: small-capex packaging, delivery tweaks\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHernia Repair and Surgical Mesh\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBD Interventional leads the mature hernia repair mesh market, with BD holding an estimated mid-20s market share in U.S. surgical mesh and fixation devices as of 2025; the category grows roughly 3-4% annually, so it generates predictable margins and cash flow.\u003c\/p\u003e\n\u003cp\u003eStrong surgeon relationships and hospital contracting lock in repeat sales, funding R\u0026amp;D into bio-resorbable materials and next-gen soft tissue repair technologies; surgical-mesh revenue contributed an estimated several hundred million dollars to BD's 2024 device sales.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLeading position; mid-20s % U.S. share (2025)\u003c\/li\u003e\n\u003cli\u003eMarket growth ~3-4% CAGR\u003c\/li\u003e\n\u003cli\u003eReliable margins, steady cash flow (hundreds of $M, 2024)\u003c\/li\u003e\n\u003cli\u003eFunds bio-resorbable and next-gen soft-tissue R\u0026amp;D\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBD's cash cows: dominant disposables, steady cash flow funding growth bets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBD's Vacutainer, syringes\/needles, peripheral IVs, ChloraPrep and hernia mesh are cash cows: \u0026gt;50% global Vacutainer share (2025), ~20B syringes demand (2024), syringe sales $2.8B (FY2024), IV catheter share 30-35% with ~$900M revenue (FY2024), ChloraPrep \u0026gt;40% US (2024), Surgical Solutions ~$3.2B (2024); low growth (~2-4% CAGR), high free cash flow funds BD's growth bets.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eShare\/Size (year)\u003c\/th\u003e\n\u003cth\u003eRevenue\/Volume (year)\u003c\/th\u003e\n\u003cth\u003eGrowth\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eVacutainer\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;50% (2025)\u003c\/td\u003e\n\u003ctd\u003eGlobal\u003c\/td\u003e\n\u003ctd\u003e2-3% CAGR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSyringes\/Needles\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003e$2.8B sales; ~20B units (2024)\u003c\/td\u003e\n\u003ctd\u003eLow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePeripheral IV\u003c\/td\u003e\n\u003ctd\u003e30-35% (2024)\u003c\/td\u003e\n\u003ctd\u003e~$900M (2024)\u003c\/td\u003e\n\u003ctd\u003e3-4% CAGR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eChloraPrep\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;40% US (2024)\u003c\/td\u003e\n\u003ctd\u003eWithin Surgical ~$3.2B (2024)\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;3% CAGR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHernia Mesh\u003c\/td\u003e\n\u003ctd\u003eMid-20s % US (2025)\u003c\/td\u003e\n\u003ctd\u003eHundreds $M (2024)\u003c\/td\u003e\n\u003ctd\u003e3-4% CAGR\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Transparency, Always\u003c\/span\u003e\u003cbr\u003eBecton Dickinson BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe file you're previewing on this page is the final Becton Dickinson BCG Matrix you'll receive after purchase-no watermarks, no demo content, just a fully formatted, analysis-ready report designed for strategic clarity and professional use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eogs\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLegacy Manual Microbiology Media\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLegacy manual plated microbiology media are in BDs Dogs quadrant: global plated media sales fell ~6% CAGR in developed markets 2019-2024 as labs shift to automated liquid culture and molecular tests; BD still sells these but market share growth \u0026lt;1% and margins under 8%, contributing minimally to 2024 BD Diagnostics revenue (~low-single-digit percent).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBasic Surgical Instruments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe market for commodity-grade manual surgical instruments is highly fragmented, with global CAGR ~1-2% and price-led competition driving margins below 10% in 2024; BD's legacy instruments face direct price pressure from emerging-market makers producing at 30-50% lower unit costs. BD's offerings show limited differentiation and accounted for under 2% of BD's 2024 revenue (~$1.6B total BD revenue), so these lines clash with BD's strategic shift to high-tech devices. Given low growth and thin margins, these SKUs are strong candidates for portfolio pruning or divestiture to redeploy capital toward faster-growing segments. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMature Urology Drainage Bags\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eStandard urinary drainage bags and basic Foley catheters sit in a low-growth, highly commoditized urology segment; global urinary catheter market grew ~1.5% in 2024, with disposables driving volume but margins shrinking. BD (Becton Dickinson) holds a relatively low share versus niche urology specialists who undercut on price-BD's urology consumables revenue was about $220m in FY2024, ≈4% of its medical segment. These products tie up management time and capex yet deliver limited returns, fitting the dog quadrant in the BCG matrix. Recent unit-price declines of ~3-5% annually cut margins further.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOlder Generation Infusion Pumps\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNon-connected, stand-alone infusion pumps without integrated safety software are rapidly becoming obsolete; global demand for legacy pumps fell ~18% from 2020-2024 while smart-pump adoption rose to ~72% of new purchases by 2024 (IQVIA\/HIMSS data), leaving BD with a small serviced installed base but minimal new-sales share.\u003c\/p\u003e\n\u003cp\u003eThese legacy devices generate low-margin, low-growth revenue-estimated single-digit percent of BD's Medication Delivery sales in 2024-and offer negligible strategic value compared with integrated platforms driving recurring consumables and software subscriptions.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eInstalled base: declining, aging units\u003c\/li\u003e\n\u003cli\u003eNew sales: \u0026lt;10% market share vs 72% smart-pumps\u003c\/li\u003e\n\u003cli\u003eRevenue: low-margin, single-digit % of segment (2024)\u003c\/li\u003e\n\u003cli\u003eStrategic value: stagnant; limited growth or stickiness\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGeneric Respiratory Consumables\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eGeneric respiratory consumables (simple oxygen masks, tubing) are Dogs: low growth (global respiratory consumables market CAGR ~1.5% 2024-29) and low share after BD divested higher-margin units in 2023-24; estimated contribution \u0026lt;1% of BD's 2024 revenue ($20.1B), roughly \u0026lt;$200M.\u003c\/p\u003e\n\u003cp\u003eCompetition from diversified suppliers lets bundles undercut BD on price; minimal R\u0026amp;D and commoditization mean negligible margin impact and likely further portfolio pruning.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLow growth: ~1.5% CAGR (2024-29)\u003c\/li\u003e\n\u003cli\u003eBD revenue share: \u0026lt;1% of $20.1B (2024)\u003c\/li\u003e\n\u003cli\u003eHigh price pressure from bundled suppliers\u003c\/li\u003e\n\u003cli\u003eMinimal innovation, low margins\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBD's low-growth \"Dogs\" (\u0026lt;5% rev): prune legacy lines to free capital for growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBD legacy plated media, manual instruments, basic urology consumables, legacy infusion pumps, and generic respiratory disposables sit in Dogs: low growth (~1-2% CAGR), low margins (\u0026lt;8-10%), and small revenue shares (each \u0026lt;5% of BD's $20.1B 2024 revenue), making them candidates for pruning or divestiture to free capital for higher-growth segments.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2024 % of BD rev\u003c\/th\u003e\n\u003cth\u003eGrowth CAGR\u003c\/th\u003e\n\u003cth\u003eMargin\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePlated media\u003c\/td\u003e\n\u003ctd\u003elow-single-digit%\u003c\/td\u003e\n\u003ctd\u003e-6% (2019-24)\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManual instruments\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;2%\u003c\/td\u003e\n\u003ctd\u003e1-2%\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;10%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUrology consumables\u003c\/td\u003e\n\u003ctd\u003e~1% (≈$220M)\u003c\/td\u003e\n\u003ctd\u003e~1.5%\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;10%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLegacy pumps\u003c\/td\u003e\n\u003ctd\u003esingle-digit % of med delivery\u003c\/td\u003e\n\u003ctd\u003e-18% (2020-24)\u003c\/td\u003e\n\u003ctd\u003elow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRespiratory disposables\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;1% (\u0026lt;$200M)\u003c\/td\u003e\n\u003ctd\u003e~1.5% (24-29)\u003c\/td\u003e\n\u003ctd\u003elow\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eQ\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euestion Marks\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAI-Integrated Digital Pathology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eBD is piloting AI-integrated digital pathology to boost diagnostic speed and accuracy; global AI pathology market was $0.6B in 2023 and is forecast to reach $3.2B by 2030 (CAGR ~26%), so upside is large.\u003c\/p\u003e\n\u003cp\u003eBD's current share in digital pathology is under 5% versus dominant imaging specialists; converting this Question Mark to a Star needs heavy R\u0026amp;D-estimated $50-100M for algorithms and validations-and regulatory filings (FDA\/CE) that can take 2-4 years.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePoint-of-Care Molecular Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe shift to decentralized testing drives a projected CAGR of ~8-12% for point-of-care molecular diagnostics to reach ~USD 7.2B by 2028 (MarketsandMarkets 2025); BD has offerings but lags earlier entrants like Cepheid (Danaher) and Abbott with smaller, faster systems. BD must choose: invest an estimated USD 200-400M to win share or reallocate R\u0026amp;D to high-throughput lab platforms that delivered \u0026gt;60% gross margins in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHome-Based Diagnostic Testing Kits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHome-based diagnostic testing kits sit in the Question Marks quadrant: global home diagnostics market projected to reach $12.8B by 2028 (CAGR ~18% from 2023), yet BD's consumer presence is minimal and brand awareness trails consumer health tech firms like Abbott and Roche Rapid. Success requires BD to build retail channels, invest in user-centered design, and likely M\u0026amp;A or partnerships; convert a small current revenue base into scaled unit sales to justify heavy capex.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAdvanced Bioprocessing Tools for Cell Therapy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBD addresses a booming cell and gene therapy market projected to reach $27.9B by 2026 (IQVIA) with targeted bioprocessing tools, but its penetration in end-to-end manufacturing is limited compared with incumbents.\u003c\/p\u003e\n\u003cp\u003eBD's strength in cell analysis offers an entry point, yet capturing workflow share will demand sustained R\u0026amp;D; 2024 R\u0026amp;D spend for BD was $1.6B, highlighting the investment scale needed.\u003c\/p\u003e\n\u003cp\u003eHigh-margin opportunity exists-CMO markets for cell therapy manufacturing grew ~35% CAGR 2019-2024-so prioritizing platform integration matters.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket size: $27.9B by 2026 (IQVIA)\u003c\/li\u003e\n\u003cli\u003eBD 2024 R\u0026amp;D: $1.6B\u003c\/li\u003e\n\u003cli\u003eCMO cell therapy manufacturing CAGR ~35% (2019-2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRemote Patient Monitoring Integration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eBD is piloting integrations of its medication delivery devices with remote patient monitoring (RPM) platforms to track adherence; RPM markets grew ~18% CAGR 2020-2025 and were ~$4.5B in 2025, but BD's digital-health revenue from these initiatives remains low versus core devices.\u003c\/p\u003e\n\u003cp\u003eProviders push RPM for chronic disease management to cut readmissions and ER visits by ~15-25%, yet BD faces strong pure-play analytics firms (e.g., Validic, Livongo-era players) and unclear market share gains-so this is a BCG Question Mark.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eMarket size 2025: ~$4.5B, CAGR ~18% (2020-2025)\u003c\/li\u003e\n\u003cli\u003eImpact: RPM reduces readmissions ~15-25%\u003c\/li\u003e\n\u003cli\u003eBD position: early penetration, low digital revenue share\u003c\/li\u003e\n\u003cli\u003eRisk: competition from established analytics\/software firms\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBD's high‑growth bets: AI pathology to cell\/gene-big markets, $50-400M to win\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eBD's Question Marks: AI pathology, point-of-care molecular, home diagnostics, cell\/gene bioprocessing, and RPM show high CAGR (AI pathology 26% to $3.2B by 2030; POC molecular to $7.2B by 2028; home diagnostics $12.8B by 2028; cell\/gene $27.9B by 2026; RPM $4.5B in 2025). Converting needs $50-400M each, 2-4 year regs, and channel\/M\u0026amp;A moves; BD R\u0026amp;D was $1.6B in 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003e2024-25 size\u003c\/th\u003e\n\u003cth\u003eCAGR\u003c\/th\u003e\n\u003cth\u003eInvestment to win\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAI pathology\u003c\/td\u003e\n\u003ctd\u003e$0.6B (2023)\u003c\/td\u003e\n\u003ctd\u003e~26%\u003c\/td\u003e\n\u003ctd\u003e$50-100M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePOC molecular\u003c\/td\u003e\n\u003ctd\u003e$7.2B (2028)\u003c\/td\u003e\n\u003ctd\u003e8-12%\u003c\/td\u003e\n\u003ctd\u003e$200-400M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHome diagnostics\u003c\/td\u003e\n\u003ctd\u003e$12.8B (2028)\u003c\/td\u003e\n\u003ctd\u003e~18%\u003c\/td\u003e\n\u003ctd\u003eChannel\/M\u0026amp;A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCell\/gene\u003c\/td\u003e\n\u003ctd\u003e$27.9B (2026)\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003ctd\u003eSustained R\u0026amp;D\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRPM\u003c\/td\u003e\n\u003ctd\u003e$4.5B (2025)\u003c\/td\u003e\n\u003ctd\u003e~18%\u003c\/td\u003e\n\u003ctd\u003ePartnerships\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"BCG Matrix","offers":[{"title":"Default Title","offer_id":44509030744147,"sku":"bd-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0709\/3102\/1907\/files\/bd-bcg-matrix.webp?v=1776711875","url":"https:\/\/bcgmatrixtemplate.com\/products\/bd-bcg-matrix","provider":"BCG Matrix","version":"1.0","type":"link"}